Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMC

Characterization and angiogenic potential of human neonatal and infant thymus mesenchymal stromal cells

Wang S., Mundada L., Johnson S., Wong J., Witt R., Ohye RG.

Laboratory Study on Cardiovascular Disease, Scar, published in Stem Cells Transl Med (2015) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Stem Cells Transl Med (2015)
Reported sample size
—
Source database
Europe PMC
PMID
25713463
PMCID
PMC4367509
DOI
10.5966/sctm.2014-0240
Citations
8

Abstract (original English)

Resident mesenchymal stromal cells (MSCs) are involved in angiogenesis during thymus regeneration. We have previously shown that MSCs can be isolated from enzymatically digested human neonatal and infant thymus tissue that is normally discarded during pediatric cardiac surgical procedures. In this paper, we demonstrate that thymus MSCs can also be isolated by explant culture of discarded thymus tissue and that these cells share many of the characteristics of bone marrow MSCs. Human neonatal thymus MSCs are clonogenic, demonstrate exponential growth in nearly 30 population doublings, have a characteristic surface marker profile, and express pluripotency genes. Furthermore, thymus MSCs have potent proangiogenic behavior in vitro with sprout formation and angiogenic growth factor production. Thymus MSCs promote neoangiogenesis and cooperate with endothelial cells to form functional human blood vessels in vivo. These characteristics make thymus MSCs a potential candidate for use as an angiogenic cell therapeutic agent and for vascularizing engineered tissues in vitro.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Thymus GlandBone Marrow CellsEndothelial CellsMesenchymal Stem CellsHumansTissue EngineeringRegenerationCell DifferentiationCell ProliferationNeovascularization, Physiologic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research